LobbyingSumitomo Pharma America lobbying by quarter
Sumitomo Pharma America's latest lobbying report covers Q1 2024, at $210K. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Sumitomo Pharma America
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $360K | 1 |
| Q1 2023 | $200K | 1 |
| Q2 2023 | $340K | 1 |
| Q3 2023 | $210K | 1 |
| Q4 2023 | $340K | 1 |
| Q1 2024 | $210K | 1 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$1.7M · 6 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES6 reports
- SENATE6 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseSumitomo Pharma America | $1.7M | 6 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/04/19for Q1 2024 | In-house | $210K |
| 24/01/22for Q4 2023 | In-house | $340K |
| 23/10/19for Q3 2023 | In-house | $210K |
| 23/07/18for Q2 2023 | In-house | $340K |
| 23/04/19for Q1 2023 | In-house | $200K |
| 23/01/20for Q4 2022 | In-house | $360K |